Rifaximin Tablets (Xifaxan)

Elliott, William T.; Chan, James
July 2010
Travel Medicine Advisor;Jul2010, Vol. 20 Issue 7, p38
The article presents a reprint of the article "Rifaximin Tablets (Xifaxan)," by William T. Elliott and James Chan, which appeared in the May 15, 2010 issue of "Internal Medicine Alert." It offers information on rifaximin, an antibacterial agent from Salix Pharmaceuticals Ltd. that has been approved for treating patients with hepatic enecephalopathy (HE). It notes that as a nonsystemic antibacterial, rifaximin has been shown to reduce the risk of HE.


Related Articles

  • Concentric Pharma Advertising. J. S. // Pharmaceutical Executive;Mar2011, Vol. 31 Issue 3, p56 

    A review is offered of a television advertisement for a treatment of hepatic encephalopathy(HE) for Salix Pharmaceuticals Ltd.

  • XIFAXAN 550mg.  // Monthly Prescribing Reference;Jul2010, Vol. 26 Issue 7, pA.19 

    The article offers information on the drug Xifaxan from Salix. The drug is part of the rifamycin class, contains the active ingredient rifaximin, and is indicated for the reduction of risk of overt hepatic encephalopathy recurrence in patients over 18 years of age. The article offers information...

  • FDA Panel Gives Solid Backing for Salix Cirrhosis Medication. Young, Donna // BioWorld Today;2/24/2010, Vol. 21 Issue 36, p1 

    The article reports that Salix Pharmaceuticals Inc.'s Xifaxan was safe and effective to treat hepatic encephalopathy (HE) according to a U.S. Food and Drug Administration (FDA) panel in Silver Spring, Maryland. HE refers to a condition in which brain function is impaired due to accumulation of...

  • Salix Pharmaceuticals Outlines Data Presentations at Digestive Disease Week 2011.  // Biomedical Market Newsletter;5/15/2011, p357 

    The article focuses on the Digestive Disease Week® (DDW) 2011 presentations that describe the investigation of various products from Salix Pharmaceuticals Ltd. such as rifaximin and MoviPrep®. It mentions several presentations on rifaximin such as the its effect in cirrhosis and recurrent...

  • Salix Pharmaceuticals Reports 1Q2011 Results.  // Biomedical Market Newsletter;5/9/2011, p414 

    The article focuses on the financial and operating results of Salix Pharmaceuticals Ltd. during the first quarter ended March 31, 2011. The company reported a total product revenue of 105.9 million dollars for the first quarter, a 140% increase from the same quarter of 2010 and a net income of...

  • Business Briefs.  // Transplant News;Apr2010, Vol. 20 Issue 4, p7 

    The article offers news briefs related to pharmaceutical companies in the U.S. The temporary approval received by SynCardia Systems Inc. from the Food and Drug Administration (FDA) to conduct a study of its Freedom driver system. The FDA's approval for the marketing of Salix Pharmaceuticals...

  • FDA Raises Endpoint Concerns in Study of Salix Liver Drug. Young, Donna // BioWorld Today;2/23/2010, Vol. 21 Issue 35, p1 

    The article focuses on the concerns raised by U.S. Food & Drug Administration (FDA) reviewers regarding the findings of a study on Xifaxan (rifaximin). The study, which was conducted by Salix Pharmaceutical Inc., examined the use of Xifaxan as a maintenance therapy for the remission of hepatic...

  • Drugmaker Shows Strong Outlook For GI Tract Treatments. MARILYN MUCH // Investors Business Daily;11/ 5/2013, pA06 

    The article reports that drugmaker Salix Pharmaceuticals Ltd. has been picking investor interest particularly on the development Xifaxan or rifaximin, an oral antibiotic for diarrhea and overt hepatic encephalopathy. It notes that Salix has achieved increased sales to 514.5 million dollars in...

  • 5D Hepatic encephalopathy.  // Monthly Prescribing Reference;Oct2016, Vol. 32 Issue 10, p86 

    The article offers information on several treatments for hepatic encephalopathy from various pharmaceutical companies. It mentions Paromomycin Sulfate from Caraco Pharmaceutical Laboratories Ltd., Xifaxan 550 mg from Salix Pharmaceuticals Ltd., and Lactulose soluton from different makers. It...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics